Table 1.
Clinical findings in 43 patients with systemic lupus erythematosus (SLE).
| ASLE | ISLE | |
|---|---|---|
| (n = 18) | (n = 25) | |
| Mean SLEDAI scores | 9.7 ± 3.2 | 1.6 ± 0.9 |
| Mean time since diagnosis | 7.6 ± 7.4 | 9.0 ± 6.0 |
| Lupus nephritis | 44.4% | 61.3% |
| Neurolupus | 0% | 19.4% |
| Lupus arthritis | 66.7% | 58.1% |
| Haematological involvement | 100% | 87.1% |
| Lupus cutaneous involvement | 77.8% | 74.2% |
| Severe Lupus* | 44.4% | 71% |
| Anti-dsDNA antibodies** | ||
| Low positive | 11.1% | 32.3% |
| Moderately positive | 22.2% | 22.6% |
| High positive | 55.6% | 6.5% |
| Treatment | ||
| Hydroxychloroquine | 94.4% | 87.1% |
| Immunossupressants*** | 66.7% | 32.3% |
| Steroids**** | 83.4% | 12.9% |
| Low dose | 46.6% | 100% |
| Moderate dose | 33.3% | 0% |
| High dose | 20.1% | 0% |
ASLE: Active disease group.
ISLE: Inactive disease group.
*Lupus severity in accordance with cumulative major organ involvement.
**Anti-dsDNA antibodies: low positive (<20 IU); moderately positive (20–50 IU); high positive (>50 IU).
***Azathioprine, mycophenolate mo1etil, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, or rituximab.
****Low dose, upto 10 mg/day; moderate dose, 10–30 mg/day; high dose, more than 30 mg/ day; n = sample investigated.